« Back
Home /
Epalrestat

Epalrestat

Item no.	HY-66009-10mM
Manufacturer	MedChem Express
CASRN	82159-09-9
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Food Safety Allergenes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.41
Citations	[1]Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55.\|[2]Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64.\|[3]Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10(3): p. 168-72.\|[4]He J, et al. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. Acta Pharmacol Sin. 2019 Jan;40(1):86-97.\|[5]Sato K, et al. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation. Redox Biol. 2013 Nov 19;2:15-21.\|[6]Li QR, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res. 2016 Feb;11(2):345-51.\|[7]Zhang T, et al. The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia. Mol Neurobiol. 2023 Jul;60(7):3741-3757.
Smiles	O=C(O)CN(C/1=O)C(SC1=C/C(C)=C/C2=CC=CC=C2)=S
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ONO2235
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	Aldose Reductase
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, protect from light)
Molecular Weight	319.40
Product Description	Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy[1][2][3].
Manufacturer - Research Area	Cancer; Metabolic Disease; Inflammation/Immunology
Solubility	DMSO: 20 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-66009-10mM-safety-datasheet.pdf